Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal FT516 and Enoblituzumab in Recurrent Ovarian Cancer
NCT04630769Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of ft516 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Masonic Cancer Center. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 28 days. Started Apr 2021; status: completed.
02
Drugs
ft516
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04630769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630769.